Boehringer Ingelheim

two baskets of eggs on a farm
Biotech

Boehringer axes MASH deal after OSE asset fails to show efficacy

The French biotech is downsizing its pipeline after its Boehringer-partnered SIRPĪ± antagonist failed to show efficacy in a phase 2 MASH study.
Gabrielle Masson Mar 2, 2026 2:16pm
Deal

Boehringer's $500M pact for oral approach to autoimmune disease

Feb 26, 2026 7:00am
x ray cystic fibrosis

Boehringer axes gene therapy after seeing cystic fibrosis data

Feb 17, 2026 1:12pm
Human kidney anatomy

Boehringer channels midstage momentum into pivotal kidney trial

Jan 28, 2026 5:39am
IBD UC CD

Boehringer pens ā‚¬1.05B deal for Simcere's IBD bispecific

Jan 27, 2026 7:30am
A ballpoint pen rests on top of a stack of documents ready for signing

Boehringer continues kidney dealmaking with $120M Variant pact

Jan 6, 2026 10:45am